Abstract
Formalised data collection on patient-reported outcomes (PROs) following treatment of early-stage breast cancer is now embedded in oncoplastic and reconstructive breast surgery.1 Most PRO studies to date pertain to invasive disease, which is likely to require adjuvant treatments that can adversely influence health-related quality of life (HRQOL). There is a dearth of information specifically relating to PROs for ductal carcinoma in situ, which has an exceptionally low mortality (3% at 20 years).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
